ISB, Covance Form Brain Tumor Partnership
Covance (NYSE: CVD), said today that its genomics laboratory in Seattle has agreed to a new collaboration with the Institute for Systems Biology to study brain tumors, according to GenomeWeb. Researchers will study the genetic differences that lurk within tumors, and find molecular targets that would enable researchers to select the right drug for the right patient. Financial terms weren’t disclosed. Covance arrived in Seattle in July 2009 when it bought the gene expression lab that was part of Merck’s Rosetta Inpharmatics unit.